United Homes Group stock plunges after Nikki Haley, directors resign
Quest Diagnostics Incorporated stock reached an all-time high of 191.87 USD, marking a significant milestone for the company. According to InvestingPro data, the company maintains a "GREAT" financial health score, reflecting its strong market position with a $21.38 billion market capitalization. This achievement comes as the stock has experienced a notable 29.83% increase over the past year, with a robust YTD return of 28%. The company’s performance reflects strong investor confidence and positive market conditions, contributing to its impressive growth trajectory. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading above its intrinsic value, though investors may find value in its 14-year consecutive dividend growth streak. As Quest Diagnostics continues to expand its offerings and strengthen its market position, the stock’s upward momentum underscores the company’s robust financial health and strategic execution. The company has demonstrated strong revenue growth of 12.58% and maintains relatively low price volatility. For deeper insights into Quest Diagnostics’ performance metrics and growth potential, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Quest Diagnostics announced several significant developments. The company has partnered with Guardant Health to expand the availability of Guardant’s Shield blood test for colorectal cancer screening through Quest’s nationwide network, with plans to make it accessible by early 2026. Additionally, Quest Diagnostics has launched a new pharmacogenomic laboratory test service to help healthcare providers tailor drug therapies based on patients’ genetic profiles. In a move to enhance laboratory services in Michigan, Quest has formed a joint venture with Corewell Health, establishing Diagnostic Lab of Michigan, LLC, which will operate from a new facility featuring advanced technologies.
Quest Diagnostics also received Breakthrough Device Designation from the FDA for its Haystack MRD test, aimed at identifying minimal residual disease in stage II colorectal cancer patients. This designation could potentially aid in determining which patients might benefit from further therapy after surgery. On the financial front, Baird downgraded Quest Diagnostics’ stock rating from Outperform to Neutral, citing a balanced risk/reward profile and limited upside potential. These recent developments reflect Quest Diagnostics’ ongoing efforts to expand its healthcare solutions and adapt to evolving medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.